Extended Data Fig. 5: Cellular, serologic, and clinical features in solid and hematologic cancer patients with COVID-19. | Nature Medicine

Extended Data Fig. 5: Cellular, serologic, and clinical features in solid and hematologic cancer patients with COVID-19.

From: CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Extended Data Fig. 5: Cellular, serologic, and clinical features in solid and hematologic cancer patients with COVID-19.The alternative text for this image may have been generated using AI.

a, Absolute counts of CD4 (Remission vs. Heme, p = 0.01; Remission vs. Solid, p = 0.02), CD8 (p = 0.02), and CD19 (Remission vs. Heme, p = 0.008; Solid vs. Heme, p = 0.0003) expression in remission (n = 11), solid cancer (n = 23), and hematologic cancer (n = 41) patients. b, Relative levels of SARS-CoV-2 IgG (p = 0.003) and IgM (p = 0.0007) in solid (n = 11) and hematologic cancer (n = 14) patients. c, Severity (NIH ordinal scale for COVID-19 clinical severity) and RT-PCR cycle threshold (remission n = 9; solid n = 25; heme n = 28) (Lower Ct: Higher viral load). d, NIH ordinal scale for COVID-19 clinical severity. (All) Significance determined by two-sided Mann Whitney test: *p < 0.05, **p < 0.01, ***p < 0.001. Median and 95% CI shown.

Back to article page